CN115279337A - 上部面纹的处理 - Google Patents

上部面纹的处理 Download PDF

Info

Publication number
CN115279337A
CN115279337A CN202180021505.4A CN202180021505A CN115279337A CN 115279337 A CN115279337 A CN 115279337A CN 202180021505 A CN202180021505 A CN 202180021505A CN 115279337 A CN115279337 A CN 115279337A
Authority
CN
China
Prior art keywords
asn
modified bont
bont
amino acid
glu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180021505.4A
Other languages
English (en)
Chinese (zh)
Inventor
N·格里戈雷
K·拉弗勒
P·皮考特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ipsen Biopharm Ltd
Original Assignee
Ipsen Biopharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ipsen Biopharm Ltd filed Critical Ipsen Biopharm Ltd
Publication of CN115279337A publication Critical patent/CN115279337A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/66—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/91—Injection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Medicinal Chemistry (AREA)
  • Birds (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Massaging Devices (AREA)
  • Percussion Or Vibration Massage (AREA)
CN202180021505.4A 2020-03-16 2021-03-16 上部面纹的处理 Pending CN115279337A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB2003813.9 2020-03-16
GBGB2003813.9A GB202003813D0 (en) 2020-03-16 2020-03-16 Treatment of upper facial lines
PCT/GB2021/050659 WO2021186167A1 (en) 2020-03-16 2021-03-16 Treatment of upper facial lines

Publications (1)

Publication Number Publication Date
CN115279337A true CN115279337A (zh) 2022-11-01

Family

ID=70453766

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180021505.4A Pending CN115279337A (zh) 2020-03-16 2021-03-16 上部面纹的处理

Country Status (11)

Country Link
US (2) US20230346674A1 (enExample)
EP (1) EP4120997A1 (enExample)
JP (2) JP2023517727A (enExample)
KR (1) KR20220154739A (enExample)
CN (1) CN115279337A (enExample)
AU (1) AU2021238928A1 (enExample)
BR (1) BR112022018457A2 (enExample)
CA (1) CA3166944A1 (enExample)
GB (1) GB202003813D0 (enExample)
TW (1) TW202140522A (enExample)
WO (1) WO2021186167A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11707510B2 (en) * 2018-02-16 2023-07-25 Preclinics Discovery Gmbh Nucleic acid-based botulinum neurotoxin for therapeutic use
US12011284B2 (en) * 2020-05-19 2024-06-18 Peachy Corp. Systems and methods for preventing and treating wrinkles
GB202206362D0 (en) * 2022-04-29 2022-06-15 Ipsen Biopharm Ltd Treatment of upper facial lines
GB202206361D0 (en) * 2022-04-29 2022-06-15 Ipsen Biopharm Ltd Treatment of a facial dystonia
GB202206348D0 (en) * 2022-04-29 2022-06-15 Ipsen Biopharm Ltd Treatment of limb spasticity
GB202214232D0 (en) 2022-09-28 2022-11-09 Ispen Biopharm Ltd Clostridial neurotoxins comprising an activating exogenous protease cleavage site
GB202214229D0 (en) 2022-09-28 2022-11-09 Ipsen Biopharm Ltd Clostridial neurotoxins comprising an activating endosomal protease cleavage site
WO2025093845A1 (en) * 2023-11-01 2025-05-08 Ipsen Biopharm Limited Use of high dose chimeric botulinum toxin a for the treatment of upper facial lines
AU2023471835A1 (en) * 2023-11-01 2026-04-30 Ipsen Biopharm Limited Use of chimeric botulinum toxin a for treating blepharospasm and hemifacial spasm
GB202318884D0 (en) 2023-12-11 2024-01-24 Ipsen Biopharm Ltd Formulation

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
IL99552A0 (en) 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
US7220422B2 (en) * 2003-05-20 2007-05-22 Allergan, Inc. Methods and compositions for treating eye disorders
DK2154151T3 (da) 2005-09-19 2011-09-05 Allergan Inc Clostridiumtoksinaktiverbare clostridiumtoksiner
EP2524963B1 (en) 2011-05-19 2018-10-31 Ipsen Bioinnovation Limited Methods for the manufacture of proteolytically processed polypeptides
MX359480B (es) 2012-05-30 2018-09-28 President And Fellows Of Harvard College Star Neurotoxina botulínica diseñada.
JP6156954B2 (ja) 2012-11-21 2017-07-05 イプセン バイオイノベーション リミテッド タンパク分解性にプロセシングされたポリペプチドの製造方法
GB201312317D0 (en) * 2013-07-09 2013-08-21 Syntaxin Ltd Cationic neurotoxins
GB201407525D0 (en) 2014-04-29 2014-06-11 Syntaxin Ltd Manufacture of recombinant clostridium botulinum neurotoxins
RU2746736C2 (ru) 2015-03-26 2021-04-20 Президент Энд Феллоуз Оф Гарвард Колледж Сконструированный ботулинический нейротоксин
GB201517450D0 (en) 2015-10-02 2015-11-18 Ipsen Biopharm Ltd Method
GB201607901D0 (en) * 2016-05-05 2016-06-22 Ipsen Biopharm Ltd Chimeric neurotoxins

Also Published As

Publication number Publication date
EP4120997A1 (en) 2023-01-25
GB202003813D0 (en) 2020-04-29
KR20220154739A (ko) 2022-11-22
TW202140522A (zh) 2021-11-01
WO2021186167A1 (en) 2021-09-23
US20230346674A1 (en) 2023-11-02
US20260207462A1 (en) 2026-07-23
JP2026097980A (ja) 2026-06-16
AU2021238928A1 (en) 2022-09-01
JP2023517727A (ja) 2023-04-26
CA3166944A1 (en) 2021-09-23
BR112022018457A2 (pt) 2022-11-01

Similar Documents

Publication Publication Date Title
US20230346674A1 (en) Treatment of Upper Facial Lines
CN115297887A (zh) 用于治疗肢体痉挛的经修饰的肉毒神经毒素
US20250179461A1 (en) Modified Bont/A for Use in the Treatment of a Disorder Affecting an Eyelid Muscle of a Subject
CN121534167A (zh) 修饰的BoNT/A用于颈肌张力障碍的治疗
AU2020357905C1 (en) Non-toxic clostridial neurotoxin polypeptides for use in treating neurological disorders
US20250177278A1 (en) Treatment of upper facial lines
US20250213662A1 (en) Bont/a for use in treating a facial dystonia
HK40078498A (en) Treatment of upper facial lines
RU2846028C1 (ru) Лечение морщин верхней части лица
RU2841585C1 (ru) Модифицированный ботулинический нейротоксин для лечения спастичности конечностей
HK40110371A (en) Modified bont/a for use in the treatment of a disorder affecting an eyelid muscle of a subject
RU2839368C1 (ru) Не токсические полипептиды клостридиального нейротоксина для применения в лечении неврологических нарушений
HK40078497A (en) Modified botulinum neurotoxin for treating limb spasticity
CN117979988A (zh) 用于治疗影响受试者眼睑肌肉的疾病的修饰的BoNT/A
WO2025093845A1 (en) Use of high dose chimeric botulinum toxin a for the treatment of upper facial lines
CN118450899A (zh) 修饰的BoNT/A用于颈肌张力障碍的治疗

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40078498

Country of ref document: HK

SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination